Randomized trial to assess safety/feasibility of memantine administration during residential treatment for alcohol use disorder: a pilot study. Issue 2 (17th February 2020)

• Record Type: Journal Article
• Authors: Lewis, Ben; Merlo, Lisa; Greene, William; Welch, Emily; Nixon, Sara Jo
• Is Part Of: Journal of addictive diseases. Volume 38:Issue 2(2019)
• Page Start: 91
• Page End: 99
• Publication Date: 2020-02-17
• Subjects: Memantine -- Namenda -- alcohol use disorder -- safety -- side effects; Substance abuse -- Periodicals; Drug abuse -- Periodicals; Alcoholism -- Periodicals; Compulsive behavior -- Periodicals; 362.2905
• DOI: 10.1080/10550887.2020.1721404
• Languages: English
• ISSNs: 1055-0887

Abstract

Abstract: The N -methyl- D -aspartate receptor (NMDAr) system is critically involved in the pathogenesis and neurobehavioral sequelae of alcohol use disorder (AUD), and constitutes a potential pharmacotherapeutic target. Memantine (Namenda) is an FDA-approved NMDAr antagonist with suggested utility in AUD, however its safety and tolerability during long-term administration among recently-detoxified patients remains uncharacterized. This pilot study assessed safety, feasibility, and several secondary measures of interest, during a 4-week period of residential AUD treatment. Participants ( N = 18) met diagnostic criteria for AUD. A double-blind, placebo-controlled, escalating-dose design was utilized. Assessments of medication side-effects were conducted weekly. At intake, week 2, and study completion, participants completed a battery assessing affective symptomatology, craving, and neurocognitive function. Medication groups reported equivalent side effects and severity. Medication compliance was high, and did not differ by group. No memantine effects were observed in secondary outcome measures. Memantine maintains a profile of high tolerability and low side-effects during post-detoxification AUD treatment. These data suggest a more aggressive dosing/escalation schedule may be used safely in future trials designed to ascertain improvements in neurocognitive function, affect, and/or craving as primary measures.